Effectiveness of Pramipexole for Treatment-Resistant Depression

NCT00231959 ↗

Phase 4 Completed 65 enrolled Massachusetts General Hospital National Institute of Mental Health (NIMH) · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the effectiveness of pramipexole (Mirapex) in managing treatment-resistant depression.

Timeline

Start: 2003-09
Primary completion: 2007-09
Completion: 2008-04

Outcome

Met primary endpoint

paper The analyses that used a mixed-effects linear regression model indicated a modest but statistically significant benefit for pramipexole (P = .038). PMID 23945458 ↗

Publications

Cusin C, Iovieno N, Iosifescu DV, Nierenberg AA, Fava M, Rush AJ, Perlis RH. A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. J Clin Psychiatry. 2013 Jul;74(7):e636-41. doi: 10.4088/JCP.12m08093.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pramipexole	Unknown	0.5 mg	—